AHA to HRSA: Implement 340B Drug Ceiling Price Rule Without Further Delay

AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers’ civil monetary penalties (CMPs) for violations of the ceiling price.

Related Resources

Webinar Recordings
Member
A panel of 4 experts discussed federal policy emerging from Congress and the Administration under COVID-19 focusing on rural health priorities and took…
Letter/Comment
Public
Dear Secretary Azar: On behalf of our nearly 2,000 340B member hospitals, the American Hospital Association (AHA) urges the Department of Health and Human…
Letter/Comment
Public
The AHA submitted its comments to the Office of Management and Budget regarding the Centers for Medicare & Medicaid Services (CMS) plans to collect pricing…
Letter/Comment
Public
The AHA urges the Department of Health and Human Services to take a number of regulatory actions that would help hospitals and health systems better…
Advisory
Member
At Issue: The Department of Homeland Security (DHS) on Feb. 24 began implementing new standards for immigration public charge decisions. When making certain…
Special Bulletin
Public
The Centers for Medicare & Medicaid Services (CMS) Feb. 20 issued a rule proposing changes to the Comprehensive Care for Joint Replacement (CJR) model,…